Pharmacopsychiatry 2002; 35(5): 190-194
DOI: 10.1055/s-2002-34120
Original Paper
© Georg Thieme Verlag Stuttgart · New York

Clozapine in Patients with Chronic Schizophrenia: Serum Level, EEG and Memory Performance

G. Adler1 , S. Grieshaber1 , V. Faude1 , B. Thebaldi1 , H. Dressing2
  • 1Clinical Neurophysiology Service
  • 2Psychiatric Day Clinic, Central Institute of Mental Health, Mannheim, Germany
Further Information

Publication History

Received: 26. 4. 2001 Revised: 5. 2. 2002

Accepted: 7. 3. 2002

Publication Date:
18 September 2002 (online)

The atypical antipsychotic clozapine causes EEG alterations, and may lead to memory impairments due to its anticholinergic properties. The relationships between clozapine serum level, quantitative EEG parameters and performance in vigilance and memory tasks were studied in a group of 17 chronically ill schizophrenic patients under maintenance treatment with clozapine at stable dosages. There were negative correlations between clozapine serum levels and the amount of high-frequency EEG activity and positive correlations between high-frequency EEG activity and memory performance. These findings may suggest that clozapine treatment brings about dose-dependent impairments of vigilance and memory, for which a reduction of high-frequency EEG activity is indicative.

References

  • 1 Baldessarini R J, Centorrino F, Flood J G, Volpicelli S A, Huston-Lyons D, Cohen B M. Tissue concentrations of clozapine and its metabolites in the rat.  Neuropsychopharmacol. 1993;  9 117-124
  • 2 Conners C K. The continuous performance test. Toronto; Multi-Health Systems 1995
  • 3 Coyle J T, Price D L, DeLong M R. Alzheimer’s disease: a disorder of central cholinergic innervation.  Science. 1983;  219 1184-1190
  • 4 Daniel D G, Goldberg T E, Weinberger D R, Kleinman J E, Pickar D, Lubick L J, Williams T S. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study.  Am J Psychiatry. 1996;  153 417-419
  • 5 Drachman D A, Leavitt J. Human memory and the cholinergic system.  Arch Neurol. 1974;  30 113-121
  • 6 Folstein M F, Folstein S E, McHugh P R. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician.  J Psychiatr Res. 1975;  12 189-198
  • 7 Freudenreich O, Weiner R D, McEvoy J P. Clozapine-induced electroencephalogram changes as a function of clozapine serum levels.  Biol Psychiat. 1997;  42 132-137
  • 8 Gattaz W F, Mayer S, Ziegler P, Platz M, Gasser T. Hypofrontality on topographic EEG in schizophrenia: correlations with neuropsychological and psychopathological parameters.  Eur Arch Psychiat Clin Neurosci. 1992;  241 328-332
  • 9 Goldberg T E, Greenberg R D, Griffin S J, Gold J M, Kleinman J E, Pickar D, Schulz S C, Weinberger D R. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia.  Br J Psychiat. 1993;  162 43-48
  • 10 Goldberg T E, Weinberger D R. The effects of clozapine on neurocognition: an overview.  J Clin Psychiatr. 1994;  55 (Suppl B) 88-90
  • 11 Green M F. What are the functional consequences of neurocognitive deficits in schizophrenia.  Am J Psychiatry. 1996;  153 321-330
  • 12 Günther W, Baghai T, Naber D, Spatz R, Hippius H. EEG alterations and seizures during treatment with clozapine.  Pharmacopsychiat. 1993;  26 69-74
  • 13 Haring C, Neudorfer C, Schwitzer J, Hummer M, Saria A, Hinterhuber H, Fleischhacker W W. EEG alterations in patients treated with clozapine in relation to plasma levels.  Psychopharmacology. 1994;  114 97-100
  • 14 Helmstaedter C, Durwen H F. VLMT: Verbaler Lern- und Merkfähigkeitstest.  Schweiz Arch Neurol Psychiat. 1990;  141 21-30
  • 15 Ihl R, Dierks T, Martin E -M, Frölich L, Maurer K. Topography of the maximum of the amplitude of EEG frequency bands in dementia of the Alzheimer type.  Biol Psychiat. 1996;  39 319-325
  • 16 Katznelson R D. EEG recording, electrode placement and aspects of generator localization. In Nuñez PL (ed) Electrical fields of the brain. New York; Oxford University Press: 1981
  • 17 Kay S R, Fiszbein A, Opler L A. The positive and negative syndrome scale (PANSS) for schizophrenia.  Schizophr Bull. 1987;  13 261-276
  • 18 Lee M A, Jayathilake K, Meltzer H Y. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia.  Schizophr Res. 1999;  37 1-11
  • 19 Malow B A, Reese K B, Sato S, Bogard H J, Malhotra A K, Su T -P, Pickar D. Spectrum of EEG abnormalities during clozapine treatment.  Electroenceph Clin Neurophysiol. 1994;  91 205-211
  • 20 McGurk S R. The effects of clozapine on cognitive functioning in schizophrenia.  J Clin Psychiatry. 1999;  60 (Suppl. 12) 24-29
  • 21 Meltzer H Y, McGurk S R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.  Schizophr Bull. 1999;  25 233-255
  • 22 Metherate R, Cox C L, Ashe J H. Cellular bases of neocortical activation: modulation of neural oscillations by the nucleus basalis and endogenous acetylcholine.  J Neurosci. 1992;  12 4701-4711
  • 23 Miller J L, Hiley C R. Anti-dopaminergic and anti-muscarinic effects of dibenzodiazepine.  Nauyn-Schmiedeberg’s Arch Pharmacol. 1976;  292 289-293
  • 24 Nordström A L, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G. D1, D2 and 5-HT2-receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients.  Am J Psychiat. 1995;  152 1444-1449
  • 25 Rey A. L’examen de clinique en psychologie. Paris; Presses Universitaires de France 1964
  • 26 Richelson E. Neuroleptics and neurotransmitter receptors.  Psychiatr Ann. 1980;  10 21-26
  • 27 Saletu B, Grunberger J, Linzmayer L, Anderer P. Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmaco-EEG and psychometry.  Pharmacopsychiat. 1987;  20 12-27
  • 28 Schuld A, Kühn M, Haack M, Kraus T, Hinze-Selch D, Lechner C, Pollmächter T. A comparison of the effects of clozapine and olanzapine on the EEG in patients with schizophrenia.  Pharmacopsychiat. 2000;  33 109-111
  • 29 Semlitsch H V, Anderer P, Saletu B, Schuster P, Presslich O. A solution for reliable and valid reduction of ocular artefacts to the P300 ERP.  Psychophysiology. 1986;  23 695-703
  • 30 Taylor L B. Psychological assessment of neurosurgical patients. In Rasmussen T, Marino R (eds) Functional neurosurgery. New York; Raven Press 1979
  • 31 Tracy J I, Monaco C A, Abraham G, Josiassen R C, Pollock B G. Relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone.  J Clin Psychiatry. 1998;  59 184-188
  • 32 Wechsler D. Psychological Corporation. New York; 1981
  • 33 Weigmann H, Hartter S, Fischer V, Dahmen N, Hiemke C. Distribution of clozapine and desmethylclozapine between blood and brain in rats.  Eur Neuropsychopharmacol. 1999;  9 253-256
  • 34 Welch J, Manschreck T, Redmond D. Clozapine-induced seizures and EEG changes.  J Neuropsychiat Clin Neurosci. 1994;  6 250-256

Georg AdlerM.D. 

Clinical Neurophysiology Service

Central Institute of Mental Health

P.O. Box 12 21 20

68072 Mannheim

Germany

Phone: +49 (621) 1703-792

Fax: +49 (621) 23 429

Email: adler@zi-mannheim.de